DocGo Inc. (DCGO) Spending and interest coverage
- R&D / revenue · 12 months: Value 4.79%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4.64%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 4.79% | Research and development expense / revenue. Period ending 2026-06-30. $14.12M ÷ $294.72M × 100 ≈ 4.79% |
| Stock-based compensation / revenue · 12 months | 4.64% | Share-based compensation / revenue. Period ending 2026-06-30. $13.67M ÷ $294.72M × 100 ≈ 4.64% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 14.12M USD | Research and Development Expense |
| Revenue | 294.72M USD | |
| Stock-based compensation | 13.67M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -183.19M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.12M | $294.72M | $13.67M | $-183.19M | (m) | 4.79% | 4.64% | (m) | (m) |
| 2026-03-31 | $13.63M | $301.71M | $15.84M | $-182.75M | (m) | 4.52% | 5.25% | (m) | (m) |
| 2025-12-31 | $13.56M | $322.20M | $17.44M | $-178.03M | (m) | 4.21% | 5.41% | (m) | (m) |
| 2025-09-30 | $13.48M | $368.09M | $18.18M | $-80.93M | (m) | 3.66% | 4.94% | (m) | (m) |
| 2025-06-30 | $13.43M | $435.97M | $16.69M | $-28.81M | (m) | 3.08% | 3.83% | (m) | (m) |
| 2025-03-31 | $12.84M | $520.50M | $14.48M | $-1.18M | (m) | 2.47% | 2.78% | (m) | (m) |
| 2024-12-31 | $11.59M | $616.56M | $13.63M | $28.69M | (m) | 1.88% | 2.21% | (m) | (m) |
| 2024-09-30 | $11.09M | $694.97M | $15.56M | $47.84M | (m) | 1.60% | 2.24% | (m) | (m) |
| 2024-06-30 | $11.18M | $742.84M | $15.77M | $46.41M | (m) | 1.50% | 2.12% | (m) | (m) |
| 2024-03-31 | $11.38M | $703.37M | $16.51M | $37.83M | (m) | 1.62% | 2.35% | (m) | (m) |
| 2023-12-31 | $10.86M | $624.29M | $20.97M | $15.05M | (m) | 1.74% | 3.36% | (m) | (m) |
| 2023-09-30 | $9.39M | $533.83M | (m) | $3.46M | (m) | 1.76% | (m) | (m) | (m) |
| 2023-06-30 | $7.53M | $451.59M | (m) | $-1.05M | (m) | 1.67% | (m) | (m) | (m) |
| 2023-03-31 | $6.11M | $435.63M | (m) | $4.83M | (m) | 1.40% | (m) | (m) | (m) |
| 2022-12-31 | $5.38M | $440.52M | (m) | $21.83M | (m) | 1.22% | (m) | (m) | (m) |
| 2022-09-30 | $5.00M | $453.05M | (m) | $37.20M | (m) | 1.10% | (m) | (m) | (m) |
| 2022-06-30 | $4.48M | $434.57M | (m) | $34.52M | (m) | 1.03% | (m) | (m) | (m) |
| 2022-03-31 | $3.89M | $386.92M | (m) | $27.33M | (m) | 1.01% | (m) | (m) | (m) |
| 2021-12-31 | $3.32M | $318.72M | (m) | $15.36M | (m) | 1.04% | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |